Clinical trials: Disabling Disease
Pulmonary Hypertension, Pulmonary Arterial Hypertension
The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
Subcutaneous treprostinil (Remodulin) is effective therapy for pulmonary arterial hypertension, a life threatening disease of the lung blood vessels.
- Trial name
- NCT01260454
- Testing
- Qutenza (8% capsaicin)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Rochester